Maurice Zauderer

This inventor holds 41 USPTO granted patents and 8 published patent applications, plus 13 CIPO patents and 16 EPO patents, primarily in Semaphorin-4D Therapy. Top assignees: Vaccinex, Inc., University of Rochester, Albert Einstein College of Medicine. Active years: 2004-2026.

USPTO Granted Patents = 41 (Patent Applications = 8)

% Patents Active = 80.5

CIPO Patents = 13 (Patent Applications = 8)

EPO Patents = 16 (Patent Applications = 19)

Average Co-Inventor Count = 2.3

ph-index = 11

Forward Citations = 321(Granted Patents)

Company Filing History:

University of Rochester

patents

2 out of 513

Albert Einstein College of Medicine

patents

4. 1 out of 1

The Sydney Children's Hospital Network

patent

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

Semaphorin-4D

Antibodies

Tumor Growth

Immune Modulation

Neurodegenerative Disorders

Blood Brain Barrier

Cancer Treatment

Therapeutics

Polynucleotides

Inflammatory Diseases

Stroke Recovery

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12668630 - HUMAN ANTI-SEMAPHORIN 4D ANTIBODY (2026-06-30),

2. 12070500 - Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis (2024-08-27),

3. 12006365 - Human anti-semaphorin 4D antibody (2024-06-11),

4. 11597765 - Use of semaphorin-4D binding molecules for the treatment of Rett syndrome (2023-03-07),

5. 11572408 - Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent (2023-02-07),

6. 11534488 - Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability (2022-12-27),

7. 11427634 - Human anti-semaphorin 4D antibody (2022-08-30),

8. 11078295 - Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases (2021-08-03),

9. 10800853 - Use of semaphorin-4D binding molecules for treating neurodegenerative disorders (2020-10-13),

10. 10662422 - Method for selecting polynucleotides encoding antigen-specific immunoglobulin subunit (2020-05-26),

11. 10526414 - Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases (2020-01-07),

12. 10494440 - Use of semaphorin-4D binding molecules to promote neurogenesis following stroke (2019-12-03),

13. 10385136 - Use of semaphorin-4D binding molecules for treating neurodegenerative disorders (2019-08-20),

14. 10111950 - Modified glycolipids and methods of making and using the same (2018-10-30),

15. 9890213 - Methods for the treatment of B cell-mediated inflammatory diseases (2018-02-13),

As an AI assistant specializing in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide information on Maurice Zauderer.

Title: Exploring the Innovations of Inventor Maurice Zauderer

Introduction: Maurice Zauderer is a prolific inventor based in Pittsford, NY, with an impressive portfolio of 40 patents to his name. His groundbreaking work has significantly impacted the fields of cancer treatment and immune modulation.

Latest Patents: Some of Maurice Zauderer's latest patents include the groundbreaking "Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis." This patent focuses on inhibiting tumor growth and metastases of Plexin-B1-expressing cancer cells by administering specific binding molecules to semaphorin-4D. Another notable patent is the "Human anti-semaphorin 4D antibody," which offers new treatment avenues for diseases associated with SEMA4D pathology.

Career Highlights: Maurice Zauderer has made significant contributions while working at companies such as Vaccinex, Inc., and the University of Rochester. His pioneering research has laid the foundation for novel approaches in treating autoimmune diseases, inflammatory conditions, cancers, and neurodegenerative disorders.

Collaborations: Throughout his career, Maurice Zauderer has collaborated with esteemed colleagues such as Ernest S Smith and Elizabeth E Evans. Elizabeth E Evans, a respected woman in the field, has worked alongside Zauderer on several innovative projects.

Conclusion: Maurice Zauderer's inventive spirit and dedication to advancing medical science have established him as a prominent figure in the field of biotechnology. His patents reflect a commitment to improving healthcare outcomes and exploring novel therapeutic avenues for complex diseases.